Caris Life Sciences stock jumped 13.7% to US$22.74 after earnings, and the emotional beat is clear. Investors focused on the headline that this is now a profitable cancer testing platform with rapid top line momentum, rather than a cash burn story. Q2 revenue reached US$263.7m and adjusted EBITDA was positive at US$55.7m, which matters in a sector where many peers still post heavy operating losses.

The key question for investors is whether this surge simply caught up with the fundamental shift or moved well ahead of it. The rest of the report helps frame that debate.

Is Caris Life Sciences now a genuine bargain after turning profitable, or just expensive growth dressed up as value? Compare the current share price to the detailed cash…